UA27706C2 - Спосіб одержання гетерологічного поліпептиду - Google Patents

Спосіб одержання гетерологічного поліпептиду

Info

Publication number
UA27706C2
UA27706C2 UA5010019A UA5010019A UA27706C2 UA 27706 C2 UA27706 C2 UA 27706C2 UA 5010019 A UA5010019 A UA 5010019A UA 5010019 A UA5010019 A UA 5010019A UA 27706 C2 UA27706 C2 UA 27706C2
Authority
UA
Ukraine
Prior art keywords
heterologous polypeptide
obtaining
obtaining heterologous
expression vector
yeast
Prior art date
Application number
UA5010019A
Other languages
English (en)
Russian (ru)
Inventor
Сорен Бьорн
Кєлд Норріс
Келд Норрис
Фанні Норріс
Фанни НОРРИС
Original Assignee
Ново Нордіск А/С
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA27706(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK494189A external-priority patent/DK494189D0/da
Application filed by Ново Нордіск А/С, Ново Нордиск А/С filed Critical Ново Нордіск А/С
Publication of UA27706C2 publication Critical patent/UA27706C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Processing Of Solid Wastes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Предметом винаходу є спосіб одержання гетерологичного поліпептиду у дріжджовій клітці, що трансформується рекомбінантним експресійним вектором. Експресійний вектор здатний реплікуватися в дріжджах і несе ДНК-конструкцію, що кодує поліпептид.
UA5010019A 1989-03-03 1990-03-01 Спосіб одержання гетерологічного поліпептиду UA27706C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK105489A DK105489D0 (da) 1989-03-03 1989-03-03 Polypeptid
DK494189A DK494189D0 (da) 1989-10-06 1989-10-06 Polypeptid
PCT/DK1990/000058 WO1990010075A1 (en) 1989-03-03 1990-03-01 Yeast processing system comprising a negatively charged amino acid adjacent to the processing site

Publications (1)

Publication Number Publication Date
UA27706C2 true UA27706C2 (uk) 2000-10-16

Family

ID=26065137

Family Applications (1)

Application Number Title Priority Date Filing Date
UA5010019A UA27706C2 (uk) 1989-03-03 1990-03-01 Спосіб одержання гетерологічного поліпептиду

Country Status (23)

Country Link
US (3) US5395922A (uk)
EP (1) EP0461165B2 (uk)
JP (1) JP2609367B2 (uk)
KR (1) KR970005928B1 (uk)
AT (1) ATE110414T1 (uk)
AU (1) AU624694B2 (uk)
CA (1) CA2050336C (uk)
CZ (1) CZ285239B6 (uk)
DD (1) DD296965A5 (uk)
DE (1) DE69011853T3 (uk)
DK (2) DK105489D0 (uk)
ES (1) ES2062514T5 (uk)
FI (1) FI104985B (uk)
HU (2) HU215538B (uk)
IE (1) IE66469B1 (uk)
IL (1) IL93609A (uk)
NO (2) NO304236B1 (uk)
NZ (1) NZ232742A (uk)
PL (1) PL163532B1 (uk)
RU (1) RU2194758C2 (uk)
UA (1) UA27706C2 (uk)
WO (1) WO1990010075A1 (uk)
ZA (1) ZA901476B (uk)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
CA2057908A1 (en) * 1989-05-19 1990-11-20 John E. Cronan, Jr. Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
GB9015825D0 (en) * 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
DE69725881T2 (de) 1996-12-13 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verfahren zur expression von heterologen proteinen in hefe
EP0946735B1 (en) * 1996-12-20 2006-02-08 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
JP2001527387A (ja) * 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ 合成リーダーペプチド配列
US6046000A (en) * 1997-11-07 2000-04-04 Millennium Biotherapeutics, Inc. Method for identifying genes encoding signal sequences
JP2003525570A (ja) 1998-01-23 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 酵母において所望のポリペプチドを産生する方法
EP1246933B1 (en) 1999-12-29 2010-07-21 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7309505B2 (en) 2002-09-13 2007-12-18 Cornell Research Foundation, Inc. Using mutations to improve Aspergillus phytases
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
CN1902226A (zh) 2003-12-03 2007-01-24 诺和诺德公司 单链胰岛素
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
EP1991576B1 (en) 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080026376A1 (en) * 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
EP2069502B1 (en) 2006-09-27 2014-02-26 Novo Nordisk A/S Method for making maturated insulin polypeptides
EP2084179B1 (en) 2006-11-22 2013-05-22 Novo Nordisk A/S Method for making activated carboxypeptidases
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
JP5710253B2 (ja) 2007-08-13 2015-04-30 ノボ・ノルデイスク・エー／エス 速効型インスリンアナログ
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
EP2406377B1 (en) * 2009-03-12 2016-01-06 Bigtec Private Limited A polynucleotide and polypeptide sequence and methods thereof
AU2010264636B2 (en) 2009-06-26 2013-06-27 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
US8815541B2 (en) 2009-11-25 2014-08-26 Novo Nordisk A/S Method for making polypeptides
ES2543634T3 (es) 2010-01-22 2015-08-20 Novo Nordisk A/S Proceso para preparación de FGF-21 con grado de O-glicosilación bajo
CN102933599A (zh) 2010-06-23 2013-02-13 诺沃—诺迪斯克有限公司 包含额外的二硫键的人胰岛素
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
RU2598273C2 (ru) 2010-06-23 2016-09-20 Ново Нордиск А/С Производные инсулина, содержащие дополнительные дисульфидные связи
MX2013006174A (es) 2010-12-14 2013-07-15 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
CN103596584B (zh) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
RU2460795C1 (ru) * 2011-07-06 2012-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") Способ микробиологического синтеза секретируемого соматотропина человека и штамм дрожжей saccharomyces cerevisiae - продуцент секретируемого соматотропина человека
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
CN103254277B (zh) * 2013-05-03 2017-02-08 南京工业大学 强分泌性信号肽增强小肽模序及其应用
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka
US10562951B2 (en) 2015-03-10 2020-02-18 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
MX2018002223A (es) 2015-08-25 2018-03-23 Novo Nordisk As Derivados de insulina novedosos y usos medicos de los mismos.
EP3341401A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
JP2018531899A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
KR102043067B1 (ko) * 2017-08-08 2019-11-11 엘지전자 주식회사 차량용 사이드 미러 및 차량
CN111032685A (zh) 2017-08-17 2020-04-17 诺沃挪第克公司 新型酰化胰岛素类似物及其用途
EP4480492A3 (en) 2019-12-11 2025-03-19 Novo Nordisk A/S Novel insulin analogues and uses thereof
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof
DE202024104234U1 (de) 2024-07-26 2024-12-18 Australian Geekkit Health Pty Ltd Peptid-Struktur-Partikel mit Signalübertragung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5712580A (en) * 1979-04-05 1980-10-09 James Joseph Connell Engine charging and scavenging
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
EP0195680A3 (en) * 1985-03-21 1987-06-10 Immunex Corporation The synthesis of protein with an identification peptide
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
MC1834A1 (fr) * 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
WO1988010299A1 (en) * 1987-06-24 1988-12-29 Novo-Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
WO1990001063A1 (en) * 1988-07-23 1990-02-08 Delta Biotechnology Limited New secretory leader sequences
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
JPH04504846A (ja) 1992-08-27
HUT58370A (en) 1992-02-28
IL93609A0 (en) 1990-12-23
ZA901476B (en) 1990-11-28
KR920701452A (ko) 1992-08-11
CA2050336A1 (en) 1990-09-04
EP0461165B1 (en) 1994-08-24
KR970005928B1 (ko) 1997-04-22
US5514585A (en) 1996-05-07
RU2194758C2 (ru) 2002-12-20
HU211600A9 (en) 1995-12-28
DE69011853D1 (de) 1994-09-29
CZ103990A3 (cs) 1999-03-17
DD296965A5 (de) 1991-12-19
IE900749L (en) 1990-09-03
FI914125A0 (fi) 1991-09-02
NO913427D0 (no) 1991-09-02
NO913427L (no) 1991-11-01
ES2062514T3 (es) 1994-12-16
DK0461165T3 (da) 1994-11-21
CZ285239B6 (cs) 1999-06-16
DK105489D0 (da) 1989-03-03
JP2609367B2 (ja) 1997-05-14
CA2050336C (en) 2000-01-18
NZ232742A (en) 1991-10-25
NO974899D0 (no) 1997-10-23
ES2062514T5 (es) 1998-06-01
HU215538B (hu) 1999-01-28
IL93609A (en) 2001-11-25
NO304236B1 (no) 1998-11-16
EP0461165A1 (en) 1991-12-18
ATE110414T1 (de) 1994-09-15
DE69011853T2 (de) 1994-12-15
EP0461165B2 (en) 1998-03-25
HU902376D0 (en) 1991-11-28
US5395922A (en) 1995-03-07
US5510249A (en) 1996-04-23
WO1990010075A1 (en) 1990-09-07
DE69011853T3 (de) 1998-06-25
IE66469B1 (en) 1995-12-27
NO974899L (no) 1997-10-23
AU5261290A (en) 1990-09-26
AU624694B2 (en) 1992-06-18
PL163532B1 (pl) 1994-04-29
FI104985B (fi) 2000-05-15

Similar Documents

Publication Publication Date Title
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
GB8610600D0 (en) Transformation of trichoderma
EP0799317B8 (en) Method for secreting thrombopoietin polypeptides
ES8802440A1 (es) Un metodo para preparar una particula que puede ser empleada como vacuna contra la infeccion por hepatitis b
BG60107B2 (bg) Метод за получаване на еукариотен полипептид
DK547185A (da) Vektorer til ekspression af hirudin, transformerede celler og fremgangsmaade til fremstilling af hirudin
EP0219106A3 (en) Polypeptides that elicit antibodies against aids virus
ES8800049A1 (es) Un metodo para la preparacion de eritropoyetina.
DK506488D0 (da) Fremgangsmaade til dyrkning af rekombinante celler, vaertscelle til anvendelse ved fremgangsmaaden og kultur omfattende vaertscellen
HUT58798A (en) Process for producing growth factor of parenchimic hepatic celles, the gen for coding this and transformants for producing this factor
NZ211357A (en) Recombinant dna and antigenic protein coded for
IL75202A0 (en) Method,vectors and transformers for high expression of heterologous polypeptides in yeast
GR3021636T3 (en) Recombinant production of PDGF A-chain polypeptides
KR880700855A (ko) 진핵생물 단백질을 발현시키는 개선된 방법
DE69634757D1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
AU604122B2 (en) An episomal vector for the expression of selected dna fragments coding for polypeptides in mammalian cells and methods for the production thereof
NZ233672A (en) Alpha amylase-pullulanase enzyme produced by recombinant techniques and its dna coding sequence
JPS6485097A (en) Recombinant human adf
AU3411889A (en) Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
AU7963487A (en) Recombinant ligninase
ATE116366T1 (de) Verfahren zur herstellung eines menschlichen ''neutrophil chemotactic factor''-polypeptids.
ES8802251A1 (es) Un procedimiento para preparar un microorganismo hospedante transformado del genero sacharomyces.
EP0183272A3 (en) Vector capable of efficient gene expression and utilization of such vector
EP0165759A3 (en) Mammalian promotors useful in yeast expression
FI861559L (fi) Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut